Ann Partridge, MD, MPH
Enriched profileChief Clinical Strategy Officer and Vice Chair, Department of Medical Oncology, Dana-Farber Cancer Institute; Eric P. Winer, MD, Chair in Breast Cancer Research; Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
Ann Partridge is Chief Clinical Strategy Officer and Vice Chair, Department of Medical Oncology, Dana-Farber Cancer Institute; Eric P. Winer, MD, Chair in Breast Cancer Research; Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 1,042 publications with 47,329 citations (h-index 102); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Ann Partridge, MD MPH, is Chief Clinical Strategy Officer and Vice Chair, Department of Medical Oncology, Dana-Farber Cancer Institute. The public record shows 1,042 publications with 47,329 citations (h-index 102), centered on Breast Cancer Treatment Studies, Cancer Risks and Factors, Cancer survivorship and care. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 4 companies, 3 NIH-funded awards (2006–2024).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Breast Cancer Treatment Studies
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 95 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 383.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Chair
CDC Advisory Committee on Breast Cancer in Young Women
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Supporting Health Including Endocrine Treatment for Long Duration
Sponsor: Dana-Farber Cancer Institute
- Optimizing Surgical Decisions in Young Adults With Breast Cancer
Sponsor: Weill Medical College of Cornell University
- INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 27 Aug 2026
4 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20253 payments
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Gilead Sciences, Inc.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor72.9%Letrozole100%Part D≥11 patientsKinase inhibitor27.1%Kisqali100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2006–2024 per NIH RePORTER. The latest:
- A web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult breast cancer survivors
Dana-Farber Cancer Inst
FY2024$695,558U01CA246648 - A web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult breast cancer survivors
Dana-Farber Cancer Inst
FY2024$222,678U01CA246648 - A web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult breast cancer survivors
Dana-Farber Cancer Inst
FY2023$695,635U01CA246648
Congress activity
Updated 27 Aug 2026
213 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- An automated, EHR-integrated intervention system for patient-reported insomnia symptoms.
ASCO Annual Meeting
ASCO2026Co-author - Sleep disorder diagnosis prevalence among adult cancer patients.
ASCO Annual Meeting
ASCO2026Co-author - Abstract 803: Elevated neuroinflammation in women with breast cancer: initial insights from [11C]PBR28 PET/MR imaging
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies.
JNCI cancer spectrum
Article2026 - A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study.
Cancer epidemiology, biomarkers & prevention
Article2026 - Health Care Utilization and Follow-Up Care in Young Adult Breast Cancer Survivors.
JCO oncology practice
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer PatientsArticle2,052 citations2006
- 03
- 04
- 05Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline UpdateArticle1,483 citations2018
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- BS
Georgetown University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗ - MPH
Harvard T.H. Chan School of Public Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Member
ASCO Board of Directors
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcrf.org ↗ - Co-chair
NCI Alliance for Clinical Trials in Oncology Breast Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcrf.org ↗ - Member
NCI Breast Cancer Steering Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcrf.org ↗
Awards & honors
honors on the public record- 2024 ESMO Award (Addressing the Unintended Consequences of Cancer Care)
European Society for Medical Oncology
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obamawhitehouse.archives.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
- Video interview
"Breast cancer in young women: Dr. Ann Partridge", Dana-Farber Cancer Institute (YouTube)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - Podcast
"Investigating Breast Cancer: Dr. Ann Partridge", Breast Cancer Research Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute